Jan 8 2015
The Musculoskeletal Transplant Foundation (MTF) Wound Care division announced today that it has signed a group purchasing agreement with Premier, Inc., a leading healthcare improvement company. The agreement offers Premier alliance members access to MTF Wound Care's innovative line of biologic tissue forms.
MTF Wound Care will initially offer Premier alliance members access to two tissue forms: AmnioBandTM Membrane, a human derived allograft placental matrix and AlloPatchTM Pliable, a human derived allograft dermal matrix.
"This is an exciting extension of our existing Premier partnership," said Kim Rounds, Vice President of MTF Wound Care. "We can now bring innovative and healing wound care solutions to Premier's patients and surgeons—many of whom already choose a broad selection of MTF tissues for their patients."
According to the National Institute of Health (NIH), treating chronic wounds is a growing concern, fueled by increasing costs, an aging population and a sharp rise in such conditions as obesity and diabetes. NIH reports that in the United States alone, more than $25 billion is spent annually to treat chronic wounds.
Given the mounting need, MTF Wound Care is dedicated to developing highly advanced, safe, clinically based and cost-effective wound care solutions that work in concert with the body's natural healing process.
They were shot at the super bowl parade — and might have bullets in their bodies forever